Powered by: Motilal Oswal
2026-01-08 10:41:13 am | Source: Reuters
India`s Torrent Pharma lines up mega $1.4 billion acquisition-funding bond sale, bankers say
India`s Torrent Pharma lines up mega $1.4 billion acquisition-funding bond sale, bankers say

India's Torrent Pharmaceuticals is set to raise up to 125 billion rupees ($1.4 billion) through short-duration bond sales in January, in one of the latest acquisition-funding deals, two bankers said.

The issuance is expected to span maturities of one to five years. Torrent also plans to raise 15 billion rupees via commercial paper to fund its acquisition of a controlling stake in JB Chemicals & Pharmaceuticals.

"The company is in the process of finalising rates and the allocation of quantum for each maturity, and once these things are finalised, they would open the issue for bidding on the electronic platform," one of the bankers said. 

Torrent Pharma did not reply to a Reuters email seeking comment. The bankers requested anonymity as they are not authorised to speak to media.

The bond issue has been rated AA+ by India Ratings and Research, which said the deal will lift Torrent Pharma’s ranking in the domestic market to fifth from seventh by market share.

Torrent has agreed to acquire a controlling stake in JB at an equity valuation of about 257 billion rupees on a fully diluted basis, to be followed by a merger of the two companies.

The bond sale would be the largest rated fund-raising so far this financial year, which runs from April to March, extending a trend of acquisitions being financed through domestic bond markets.

JSW Group raised 70 billion rupees via zero-coupon bonds in September to fund the purchase of up to a 75% stake in the Indian unit of Dutch paint maker Akzo Nobel.

Two Jubilant Bhartia Group subsidiaries raised a combined 56.50 billion rupees through zero-coupon bonds in June to fund the acquisition of a 40% stake in Hindustan Coca-Cola Holdings.

($1 = 89.9170 Indian rupees)

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here